13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-004868-95-ES
(EUCTR)
26/05/202222/12/2021AMANTADINE AND TRANSCRANIAL MAGNETIC STIMULATION FOR TREATING FATIGUE IN MULTIPLE SCLEROSISAMANTADINE AND TRANSCRANIAL MAGNETIC STIMULATION FOR TREATING FATIGUE IN MULTIPLE SCLEROSIS: PHASE III STUDY, CONTROLLED, RANDOMIZED, CROSSED OVER AND DOUBLE BLIND - FETEM Fatigue in multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Amantadine Level
Product Name: Amantadine
INN or Proposed INN: INN
Other descriptive name: AMANTADINE HYDROCHLORIDE
Fundación para la Inv. Biomédica Hospital Clínico San CarlosNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
144Phase 4Spain
2NCT03567057
(ClinicalTrials.gov)
July 18, 201822/5/2018A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentA Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking ImpairmentMultiple Sclerosis;Walking ImpairmentDrug: ADS-5102, 274 mgAdamas Pharmaceuticals, Inc.NULLCompleted18 Years70 YearsAll424Phase 3United States;Canada
3NCT03436199
(ClinicalTrials.gov)
March 29, 201812/2/2018Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentA 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking ImpairmentWalking Impairment;Multiple SclerosisDrug: ADS-5102, 137 mg;Drug: ADS-5102, 274 mg;Other: PlaceboAdamas Pharmaceuticals, Inc.NULLCompleted18 Years70 YearsAll558Phase 3United States;Canada
4NCT03185065
(ClinicalTrials.gov)
October 4, 20179/6/2017Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple SclerosisTreatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple SclerosisFatigue in Multiple SclerosisDrug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: PlacebosJohns Hopkins UniversityPatient-Centered Outcomes Research InstituteCompleted18 YearsN/AAll141Phase 3United States
5NCT02471222
(ClinicalTrials.gov)
May 201511/6/2015Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentSafety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking ImpairmentWalking Impairment;Multiple SclerosisDrug: ADS-5102;Other: PlaceboAdamas Pharmaceuticals, Inc.NULLCompleted18 Years70 YearsAll60Phase 2United States
6EUCTR2012-003418-15-AT
(EUCTR)
23/10/201209/11/2012Methylphenidate modified release as treatment of MS-associated fatigue.Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial. Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step pharmacologic therapy. Until now, Amantadine, Modafinil or antidepressants have been used off-label among others, with some success. Until now, methylphenidate has been successfully used to treat fatigue in HIVand parkinson´s disease, data on its efficacy in MS are not available.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Ritalin LA 20mg capsules
Product Name: Methylphenidate modified release 20 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Trade Name: Ritalin LA 30mg capsules
Product Name: Methylphenidate modified release 30 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Trade Name: Ritalin LA 40mg capsules
Product Name: Methylphenidate modified release 40 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Medizinische Universität WienNULLNot RecruitingFemale: yes
Male: yes
96Phase 2Austria
7EUCTR2010-023678-38-IT
(EUCTR)
20/04/201102/02/2011High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - NDHigh-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND patients with multiple sclerosis
MedDRA version: 9.1;Level: PT;Classification code 10028245
Trade Name: MANTADAN*20CPR 100MG
INN or Proposed INN: Amantadine
Trade Name: AMPYRA
INN or Proposed INN: Ampyra
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABORNULLNot RecruitingFemale: yes
Male: yes
Italy